¥xÆW°ÊÃÄQ4µn¿³Âd
¥xÆW°ÊÃĬQ¤Ñ»P¸s¯qª÷¹©ÃÒ¨éñ¬ù¡A¹wp¤µ¦~©³µn¿ý¿³Âd¥æ©ö¡A©ú¦~¤WÂd¡Cº¤äÃdª«§ÜÀù·sÃÄTD-B10¹wp©ú
¥xÆW°ÊÃĬQ¤Ñ»P¸s¯qª÷¹©ÃÒ¨éñ¬ù¡A¹wp¤µ¦~©³µn¿ý¿³Âd¥æ©ö¡A©ú¦~¤WÂd¡Cº¤äÃdª«§ÜÀù·sÃÄTD-B10¹wp©ú¦~¥Ó½Ð¥xÆWÃÄÃÒ¡A«á¦~¥Ó½Ð°ê»ÚÃÄÃÒ¡A·m§ð¼Æ¤Q»õ¬ü¤¸°Ó¾÷¡C
¥xÆW°ÊÃĦ¨¥ß©ó2012¦~¡A¬O¨È¬wº®a¡B¤]¬O¥xÆWº®a°Êª«§ÜÀù·sÃĤ½¥q¡Cº¤äÃdª«§ÜÀù·sÃÄTD-B10¡A¬O¸³¨Æªø³¯«Ø§»10¦h¦~ªº¬ãµo¦¨ªG¡A¤w©ó¥x¤j¡B¤¤¿³Âå°|§¹¦¨Á{§É¹w¸ÕÅç(pilot study)¡A¹wp©ú¦~¥Ó½Ð¥xÆWÃÄÃÒ¡A«á¦~±Ò°Ê°ê»Ú¥«³õ¥¬§½¡A·m§ð¼Æ¤Q»õ¬ü¤¸°Ó¾÷¡C
³¯«Ø§»»¡¡A¥Ø«e¥þ²y°ß¤@ªºÃdª«§ÜÀùÃĬO½÷·çÃļt(Pfizer)ªºPalladia¡AÄÝ©ó¼Ð¹v¥ÎÃÄ¡A¸ÕÅçµ²ªGÃÒ¹ê¶È¹ï36%ªº¸~½F¦³´î½w¯fµ{ªº¥\®Ä¡C¬Û¸û¤§¤U¡ATD-B10ªºÃĮĤñPalladia¦n¡B°Æ§@¥Î§C¡B¾A¥Î½d³ò§ó¦n¡C
¥L«ü¥X¡A®Ú¾Ú¹êÅç¼Æ¾ÚÅã¥Ü¡A25°¦¸~½F±w¤ü¤¤¡A¦³16°¦¹F¨ì¨}¦nªºªvÀø®ÄªG¡A¤@©PÀøµ{³Ì¤pªº¸~½F®ø°h±¿n³£¦³30%¥H¤W¡C
³¯«Ø§»«ü¥X¡A®Ú¾Ú²Îp¡A¬ü°ê°Êª«¥ÎÃÄ¥«³õ±q2011¦~ªº66.8»õ¬ü¤¸¡A¹w¦ô2015¦~±N¦¨ªø¦Ü92.5»õ¬ü¤¸¡A°Ó¾÷Ãe¤j¡CTD-B10¤w¨ú±o¬ü°ê¡B¤é¥»¡B«Xù´µ¡B¯Ã¦èÄõ¡B¿D¬w¡B¤¤°ê¤j³°µ¥¦h°ê±M§Q¡A¨Ã¦³°ê¤º¼Æ¤Q®aÂå°|ªí¹F¦X§@¿³½ì¡A¹ï¤½¥q«e´º¼ÖÆ[¬Ý«Ý¡C
¸s¯qª÷¹©ÃÒ¨éÁ`¸g²z»¯¥Ã¸ªí¥Ü¡A¥þ²y°Êª«¥ÎÃÄ¥«³õ¦¨ªø¼ç¤OÃe¤j¡A¥xÆW°ÊÃĪº¬ãµo¹ê¤OÀu²§¡A°t¦X¬F©²¹ï©ó¥Í§Þ²£·~ªº¤ä«ù¡A¬Û«H¥xÆW°ÊÃıN¦¨¬°¸ê¥»¥«³õªº©ú¤é¤§¬P¡A±a°Ê°Êª«¥ÎÃIJ£·~¤W¥«ªº·¼é¡C
¡i¤¤¥¡ªÀ¡j
§@ªÌ¤¶²Ð